Platelet-Rich Plasma for Hair Loss: Update and Expert Q&A
According to estimates from the National Institutes of Health, androgenic alopecia affects 30 million women and 50 million men in the United States.
According to estimates from the National Institutes of Health, androgenic alopecia affects 30 million women and 50 million men in the United States.
PF-06700841 and PF-06651600 were found to have an effect onset of 6 and 4 weeks, respectively in patients with moderate to severe alopecia areata.
Dupilumab, commonly used for eczema, may be effective for hair regrowth in patients with alopecia totalis and atopic dermatitis.
Complete or near-complete hair regrowth occurred in 5 patients, with a 98% improvement in the Severity of Alopecia Tool score.
Hair growth outcomes with contact immunotherapy for alopecia areata were associated with many factors and there was a significant variability in the criteria used.
Patients with alopecia areata may have multiple risk factors for mental health disorders, including psychological distress and impaired quality of life.
For patients with breast cancer, endocrine therapy-induced alopecia has a pattern that is similar to androgenetic alopecia.
Patients were most often affected by feelings of embarrassment and self-consciousness, followed by effects on social and leisure activities.
Carboxytherapy is a promising therapeutic treatment option for patchy alopecia areata and could be used as an adjuvant therapy of androgenetic alopecia.
The FDA has granted Fast Track designation for CTP-543, a novel oral Janus kinase inhibitor for the treatment of moderate-to-severe alopecia areata, which currently has no approved treatments.